Belgian drugmaker UCB has inked a $480 million deal to team up with Neuropore Therapies on some early-stage treatments for Parkinson's disease.
Improved access by researchers to corporate clinical trial data, much like open-source software, is expected to help facilitate a conversation between academia and the business world that could both facilitate translational research and help to validate corporate research. Yale University and Johnson & Johnson have announced the first such deal to enable external investigator access to medical device and diagnostics clinical data from J&J.
Partners Intrexon and Ziopharm are cutting in on the fervor over a new class of immunotherapies for cancer, striking a deal with the University of Texas' MD Anderson Cancer Center.
New Jersey capsule technology specialist Capsugel has picked up a drug delivery platform developed at Australia's Monash University that makes use of lipidlike counter-ion salts to improve the bioavailability of certain drugs.
Scientists don't fully understand what causes Alzheimer's disease yet and success on the vaccines front has been limited, but Johnson & Johnson and Swiss biopharma AC Immune will nonetheless be partnering to develop a therapeutic vaccine for the disease.
Eli Lilly is buying big into the idea that the latest and greatest cancer therapies can work even better in combination, inking agreements to study its drugs alongside immunotherapies from Merck and Bristol-Myers Squibb.
Pharma giant Merck is buying into the allure of Moderna Therapeutics and its radical promise to transform patients' cells into drug factories, committing $100 million and joining a host of collaborators and investors betting the early-stage biotech is sitting on transformational technology.
J&J subsidiary Janssen Biotech has inked a deal to collaborate with Boston-based Vedanta on a new bacterial treatment for inflammatory bowel disease, or IBD. And it handed over an undisclosed upfront payment and promises of up to $241 million in milestones if their partnership can blaze a path to the market eventually.
Following through on its sweeping return to antibiotics R&D, Roche has agreed to pay up to $750 million to get its hands on an early-stage drug that helps existing treatments battle drug-resistant infections.
San Diego-based oncology diagnostics outfit Biocept is teaming up with Insight Genetics of Nashville to develop an improved diagnostic for the most common type of lung cancer.